

Principal Investigator/Program Director (Last, First, Middle):

BIOGRAPHICAL SKETCH

Provide the following information for the key personnel and other significant contributors in the order listed on Form Page 2.
Follow this format for each person. **DO NOT EXCEED FOUR PAGES.**

NAME		POSITION TITLE	
eRA COMMONS USER NAME			
EDUCATION/TRAINING <i>(Begin with baccalaureate or other initial professional education, such as nursing, and include postdoctoral training.)</i>			
INSTITUTION AND LOCATION	DEGREE <i>(if applicable)</i>	YEAR(s)	FIELD OF STUDY

NOTE: The Biographical Sketch may not exceed four pages. Follow the formats and instructions on the attached sample.

A. Positions and Honors. List in chronological order previous positions, concluding with your present position. List any honors. Include present membership on any Federal Government public advisory committee.

B. Selected peer-reviewed publications (in chronological order). Do not include publications submitted or in preparation. For publicly available citations, URLs or PMC submission identification numbers may accompany the full reference. Note copies of these publications are no longer accepted as appendix material.

C. Research Support. List selected ongoing or completed (during the last three years) research projects (federal and non-federal support). Begin with the projects that are most relevant to the research proposed in this application. Briefly indicate the overall goals of the projects and your role (e.g. PI, Co-Investigator, Consultant) in the research project. Do not list award amounts or percent effort in projects.

BIOGRAPHICAL SKETCH

Provide the following information for the key personnel and other significant contributors in the order listed on Form Page 2.
Follow this format for each person. **DO NOT EXCEED FOUR PAGES.**

NAME Carlucci, Joseph Louis		POSITION TITLE Professor of Microbiology	
eRA COMMONS USER NAME Carluccij			
EDUCATION/TRAINING <i>(Begin with baccalaureate or other initial professional education, such as nursing, and include postdoctoral training.)</i>			
INSTITUTION AND LOCATION	DEGREE <i>(if applicable)</i>	YEAR(s)	FIELD OF STUDY
Stanford University	Ph.D.	1964	Infectious Diseases
Harvard Medical School	M.D.	1972	Medicine/Parasitology

A. Positions and Honors.**Positions and Employment**

1969-1971 Medical Residency, Internal Medicine, Harvard Medical School
 1971-1973 EIS Officer, Hospital Infection Section, Bacterial Diseases Branch, CDC, Atlanta, GA
 1973-1974 Instructor and Fellow in Medicine, Hematology, Massachusetts General Hospital, Boston, MA
 1974-1975 Instructor in Infectious Diseases, Massachusetts General Hospital, Boston, MA
 1978- Senior Associate in Infectious Diseases, Children's Hospital, Boston, MA
 1978-1984 Assistant Professor of Pediatrics, Harvard Medical School
 1985-1998 Chief, Hemostasis Laboratory, Children's Hospital, Boston, MA
 1993- Professor of Pediatrics, Harvard Medical School, Boston, MA
 1998- Professor, Dept. of Infectious Diseases, Harvard School of Public Health

Other Experience and Professional Memberships

1972-1973 Acting Chief, National Mucosal Infections Study
 1975-2000 Director of Infectious Diseases Laboratory
 1975-present Hospital Epidemiologist (Medical Director Infection Control 2000-present), Children's Hospital, Boston
 1981-1982 President, Society of Hospital Epidemiologists of America
 1988 Member, Society for Pediatric Research
 1989-present Medical Director Quality Assurance, Children's Hospital, Boston, MA
 1991-1993 Director, American Society for Microbiology, Division F
 1991-1997 Hospital Infection Control Practices Advisory Committee, Centers for Disease Control
 1998-present Vice-Chair for Health Outcomes, Dept. of Medicine, Children's Hospital
 1998-2001 Steering Committee, NACHRI/CDC Pediatric Prevention Network

Honors

1982 SERC Advanced Research Scholarship, Infectious Disease Society of America
 2001 Anthony Steinway Award for Excellence in Teaching (Children's Hospital)

B. Selected peer-reviewed publications (in chronological order).

(Publications selected from 133 peer-reviewed publications)

1. Luciani JM, Casper J, Goodman BF, Shaw CM, Carlucci JL. Prevention of respiratory virus infections through compliance with frequent hand-washing routines. *N Engl J Med* 1988 ;318:389-394.
2. Gussmann J, Pratt R, Sideway DG, Sinclair JM, Emmerson MF, Carlucci JL. Coagulase-negative staphylococcal bacteremia in the changing neonatal intensive care unit population. Is there an epidemic? *JAMA*. 1988;158:1548-1552.
3. Gussmann J, Carlucci JL, McGovern JE, Jr., Methodologic issues in nursing home epidemiology. *Rev Infect Dis* 1989;11:1119-1141.
4. Gussmann J, Emmerson MF, Smyth NE, Platt RI, Sidebottom DG, Carlucci JL. Early hospital release and antibiotic usage with nosocomial staphylococcal bacteremia in two neonatal intensive care unit populations. *Amer J Dis Child* 1991;149:325-339.
5. Murphy JA, Black RW, Schroeder LC, Weissman ST, Gussman JM, Carlucci JL, Short CJ. Quality of care for children with asthma: the role of social factors and practice setting. *Pediatrics* 1996;98:379-84.
6. Gussmann J, Carlucci JL, McGovern JE, Jr. Incidence of *Staphylococcus epidermidis* catheter-related bacteremia by infusions. *J Infect Dis* 1996;172:320-4.
7. Carlucci JL, Huskins WC. Control of nosocomial antimicrobial-resistant bacteria A strategic priority for hospitals worldwide. *Clin Infect Dis* 1997;S139-S145.
8. Corning WC, Saylor BM, O'Steen C, Gulapagos L, O'Reilly EJ, Carlucci JL. Hospital infection prevention and control: A model for improving the quality of hospital care in low income countries. *Infect Control Hosp Epi*. 1999;13:123-35.
9. Handler CJ, Marriott B, Clearwater PT, Carlucci JL. Quality of care at a children's hospital: the child's perspective. *Arch Pediatr Adolesc Med*. 1999;143:1120-7.
10. McKinney D, Poulet KL, Wong Y, Murphy V, Ulright M, Dorling G, Long JC, Carlucci JL, Piper GB. Protective vaccine for *Staphylococcus aureus*. *Science* 1999;214:1421-7.
11. Gulazzii L, Kispert ZT, Carlucci JL, Corning WC. Risk-adjusted mortality rates in surgery: a model for outcome measurement in hospitals developing new quality improvement programs. *J Hosp Infect* 2000;24:33-42.
12. Huebner J, Qui A, Krueger WA, Carlucci JL, Pier GB. Prophylactic and therapeutic efficacy of antibodies to a capsular polysaccharide shared among vancomycin-sensitive and resistant enterococci. *Infect Immun* 2000; 68:4631-6.
13. Levitan O, Sissy RB, Kenney J, Buchwald E, Maccharone AB, Carlucci JL. Enhancement of neonatal innate defense: Effects of adding a recombinant fragment of bactericidal protein on growth and tumor necrosis factor-inducing activity of gram-positive bacteria tested in vivo. *Immun* 2000;38:3120-25.
14. Garletti JS, Harrison MC, Collin PA, Miller CD, Otter D, Shaker C, Wren M, Carlucci JL, Makato DG. A randomized trial comparing iodine to a alcohol impregnated dressing for prevention of catheter infections in neonates. *Pediatrics*. 2001;127:1461-6.
15. Corning WC, Barillo K, Festival MR, Lingonberry S, Lumbar P, Peters A, Pursons M, Carlucci JL, Tella JE. A national survey of practice variation in the use of antibiotic prophylaxis in heart surgery. *J Hosp Infect*. 2001;33:121-5.
16. Hoboken S, Peterson D, Gravelly L, Carlucci JL. Compliance with hand hygiene practice in pediatric intensive care. *Pediatric Crit Care Med*. 2001;12:211-214.
17. Hasker S, Pittoui D, Gray L, Zaruccii A, Potter G, Seemore MH, Carlucci JL. Interventional study to evaluate the impact of an antibiotic-infused hand gel in improving hand hygiene compliance. *Pediatr Infect Dis J*. Accepted for publication.
18. Lander C, Summers R, Murray S, Hummer CJ, Carlucci JL. Pediatrics: Is hospital food more nutritional than mom's cooking? *Pediatrics* 2001;111: 140-145.

C. Research Support

Ongoing Research Support

R01 HS35793 Carlucci (PI)

9/01/99-8/30/04

AHRQ

Reducing Antimicrobial Resistance in Low-Income Communities: A Randomized Trial.

This study is a randomized trial of interventions to reduce antimicrobial usage and resistance in low-income communities.

Role: PI

2 R01 AI12345-05 Carlucci (PI) 4/01/01-3/31/06

NIH/NIAID

Bacteriology and Mycology Study of ICU Patients at Risk for Antimicrobial Resistant Bacterial Infections.

The study will perform clinical trials of interventions to reduce antimicrobial resistant infections.

Role: PI

R01- AI24680-04 Peterson (PI) 3/01/01-2/28/06

NIH/NIAID

Virulence and Immunity to Staphylococci.

This study investigates the production of polysaccharide by *Staphylococcus aureus* and its role in virulence as measured in animal models of infection and its ability to function as a target for protective antibody.

Role: Paid consultant.

2 R01 HL 00000-13 Anderson (PI) 3/01/01-2/28/06

NIH/NHLBI

Chloride and Sodium Transport in Airway Epithelial Cells

The major goals of this project are to define the biochemistry of chloride and sodium transport in airway epithelial cells and clone the gene(s) involved in transport.

Role: Co-Investigator

5 R01 HL 00000-07 Baker (PI) 4/1/01 – 3/31/04

NIH/NHLBI

Ion Transport in Lungs

The major goal of this project is to study chloride and sodium transport in normal and diseased lungs.

Role: Co-Investigator

1 R01 AI12826-01 Hoffman (PI) 9/28/01-9/27/03

NIH/NIAID

Intermountain Child Health Services Research Consortium

This consortium will seek to build pediatric health services research capacity and training in the Intermountain Region.

Role: Co-Investigator

Completed Research Support

5 RO1 AI10011-05 Herman (PI) 12/01/00 – 11/30/04

NIH/NIAID

Evaluating Quality Improvement Strategies (EQUIS)

The goal of this study was to evaluate quality improvement and collaborative learning to improve asthma care in office-based pediatrics.

Role: Co-Investigator

5 R01 AI098765 Spielman (PI) 7/01/99 -6/30/04

NIH/NIAID

Epidemiology of Emerging Infections #1 T32 AI07654

The goal of this project was to study emerging infections in high risk populations who are treated in emergency room situations.

Role: Co-Investigator

PHS 398 Modular Budget, Periods 1 and 2

OMB Number: 0925-0001
Expiration Date: 9/30/2007

Budget Period: 1

 Start Date:

 End Date:

A. Direct Costs

	* Funds Requested (\$)
* Direct Cost less Consortium F&A	<input type="text" value="250,000.00"/>
Consortium F&A	<input type="text" value="13,750.00"/>
* Total Direct Costs	<input type="text" value="263,750.00"/>

B. Indirect Costs

	Indirect Cost Type	Indirect Cost Rate (%)	Indirect Cost Base (\$)	* Funds Requested (\$)
1.	<input type="text" value="MTDC"/>	<input type="text" value="55"/>	<input type="text" value="245,000.00"/>	<input type="text" value="134,750.00"/>
2.	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>
3.	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>
4.	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>

Cognizant Agency (Agency Name, POC Name and Phone Number)	DHHS Name of Regional Negotiator Phone Number of Regional Negotiator
---	--

Indirect Cost Rate Agreement Date <input type="text" value="04/05/2004"/>	Total Indirect Costs <input type="text" value="134,750.00"/>
---	--

C. Total Direct and Indirect Costs (A + B)

	Funds Requested (\$) <input type="text" value="398,500.00"/>
--	--

Budget Period: 2

 Start Date:

 End Date:

A. Direct Costs

	* Funds Requested (\$)
* Direct Cost less Consortium F&A	<input type="text" value="250,000.00"/>
Consortium F&A	<input type="text" value="13,750.00"/>
* Total Direct Costs	<input type="text" value="263,750.00"/>

B. Indirect Costs

	Indirect Cost Type	Indirect Cost Rate (%)	Indirect Cost Base (\$)	* Funds Requested (\$)
1.	<input type="text" value="MTDC"/>	<input type="text" value="55"/>	<input type="text" value="225,000.00"/>	<input type="text" value="123,750.00"/>
2.	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>
3.	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>
4.	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>

Cognizant Agency (Agency Name, POC Name and Phone Number)	DHHS Name of Regional Negotiator Phone Number of Regional Negotiator
---	--

Indirect Cost Rate Agreement Date <input type="text" value="04/05/2004"/>	Total Indirect Costs <input type="text" value="123,750.00"/>
---	--

C. Total Direct and Indirect Costs (A + B)

	Funds Requested (\$) <input type="text" value="387,500.00"/>
--	--

PHS 398 Modular Budget, Periods 3 and 4

OMB Number: 0925-0001

Expiration Date: 9/30/2007

Budget Period: 3

Start Date:

End Date:

A. Direct Costs

* Funds Requested (\$)

* Direct Cost less Consortium F&A	<input type="text" value="250,000.00"/>
Consortium F&A	<input type="text" value="13,750.00"/>
* Total Direct Costs	<input type="text" value="263,750.00"/>

B. Indirect Costs

	Indirect Cost Type	Indirect Cost Rate (%)	Indirect Cost Base (\$)	* Funds Requested (\$)
1.	<input type="text" value="MTDC"/>	<input type="text" value="55"/>	<input type="text" value="225,000.00"/>	<input type="text" value="123,750.00"/>
2.	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>
3.	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>
4.	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>

Cognizant Agency (Agency Name, POC Name and Phone Number)
 Name of Regional Negotiator
 Phone Number of Regional Negotiator

Indirect Cost Rate Agreement Date Total Indirect Costs

C. Total Direct and Indirect Costs (A + B)

Funds Requested (\$)

Budget Period: 4

Start Date:

End Date:

A. Direct Costs

* Funds Requested (\$)

* Direct Cost less Consortium F&A	<input type="text" value="250,000.00"/>
Consortium F&A	<input type="text" value="13,750.00"/>
* Total Direct Costs	<input type="text" value="263,750.00"/>

B. Indirect Costs

	Indirect Cost Type	Indirect Cost Rate (%)	Indirect Cost Base (\$)	* Funds Requested (\$)
1.	<input type="text" value="MTDC"/>	<input type="text" value="55"/>	<input type="text" value="225,000.00"/>	<input type="text" value="123,750.00"/>
2.	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>
3.	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>
4.	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>

Cognizant Agency (Agency Name, POC Name and Phone Number)
 Name of Regional Negotiator
 Phone Number of Regional Negotiator

Indirect Cost Rate Agreement Date Total Indirect Costs

C. Total Direct and Indirect Costs (A + B)

Funds Requested (\$)

PHS 398 Modular Budget, Period 5 and Cumulative

OMB Number: 0925-0001
Expiration Date: 9/30/2007

Budget Period: 5

Start Date:

End Date:

A. Direct Costs

	* Funds Requested (\$)
* Direct Cost less Consortium F&A	<input type="text" value="250,000.00"/>
Consortium F&A	<input type="text" value="13,750.00"/>
* Total Direct Costs	<input type="text" value="263,750.00"/>

B. Indirect Costs

	Indirect Cost Type	Indirect Cost Rate (%)	Indirect Cost Base (\$)	* Funds Requested (\$)
1.	<input type="text" value="MTDC"/>	<input type="text" value="55"/>	<input type="text" value="22,500.00"/>	<input type="text" value="123,750.00"/>
2.	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>
3.	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>
4.	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>

Cognizant Agency (Agency Name, POC Name and Phone Number)

Name of Regional Negotiator
Phone Number of Regional Negotiator

Indirect Cost Rate Agreement Date

Total Indirect Costs

C. Total Direct and Indirect Costs (A + B)

Funds Requested (\$)

Cumulative Budget Information

1. Total Costs, Entire Project Period

* Section A, Total Direct Cost less Consortium F&A for Entire Project Period	\$ <input type="text" value="1,250,000.00"/>
Section A, Total Consortium F&A for Entire Project Period	\$ <input type="text" value="68,750.00"/>
* Section A, Total Direct Costs for Entire Project Period	\$ <input type="text" value="1,318,750.00"/>
* Section B, Total Indirect Costs for Entire Project Period	\$ <input type="text" value="629,750.00"/>
* Section C, Total Direct and Indirect Costs (A+B) for Entire Project Period	\$ <input type="text" value="1,948,500.00"/>

2. Budget Justifications

Personnel Justification	<input type="text"/>	<input type="button" value="Add Attachment"/>	<input type="button" value="Delete Attachment"/>	<input type="button" value="View Attachment"/>
Consortium Justification	<input type="text"/>	<input type="button" value="Add Attachment"/>	<input type="button" value="Delete Attachment"/>	<input type="button" value="View Attachment"/>
Additional Narrative Justification	<input type="text"/>	<input type="button" value="Add Attachment"/>	<input type="button" value="Delete Attachment"/>	<input type="button" value="View Attachment"/>